Metraipolis › archive › dc_d5708bca47e6

A post-marketing surveillance study on the safety and effectiveness of recombinant antithrombin gamma in patients with congenital antithrombin deficiency in… — Europe PMC PMID:41761262

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41761262
DOI
10.1186/s12959-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-11-05T13:07:42.315Z
SHA-256 of the archived text
cf5d26cffc500878d8ae317aeeb4bd05631793dbe29ca4e1f1ed5427a46cc48c
Stable URL of this page
https://metraipolis.com/documento/dc_d5708bca47e6

How to cite

A post-marketing surveillance study on the safety and effectiveness of recombinant antithrombin gamma in patients with congenital antithrombin deficiency in… — Europe PMC PMID:41761262 — Europe PMC (en), https://europepmc.org/article/MED/41761262 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d5708bca47e6 (Metraipolis archive dc_d5708bca47e6, sha256 cf5d26cffc500878d8ae317aeeb4bd05631793dbe29ca4e1f1ed5427a46cc48c)
BibTeX
@misc{dcd5708bca47e6,
  title = {A post-marketing surveillance study on the safety and effectiveness of recombinant antithrombin gamma in patients with congenital antithrombin deficiency in… — Europe PMC PMID:41761262},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41761262},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d5708bca47e6; sha256 cf5d26cffc500878d8ae317aeeb4bd05631793dbe29ca4e1f1ed5427a46cc48c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41761262. Agents can read the archived copy with the MCP tool read_document.